Open AccessTenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa
Author(s) -
Lauren Jennings,
Reuben N Robbins,
Nadia Nguyen,
Christopher Ferraris,
Cheng-Shiun Leu,
Curtis Dolezal,
Nei-Yuan Hsiao,
Ofole Mgbako,
John Joska,
José CastilloMancilla,
Landon Myer,
Peter L. Anderson,
Robert H. Remien,
Catherine Orrell
Publication year - 2022
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000003185
Subject(s) - viral load , medicine , viremia , dried blood spot , odds ratio , logistic regression , cohort , dried blood , prospective cohort study , antiretroviral therapy , confidence interval , cohort study , tenofovir , human immunodeficiency virus (hiv) , immunology , biology , chemistry , genetics , chromatography
Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is used as a biomarker of antiretroviral therapy (ART) adherence. Recent treatment studies have shown that TFV-DP predicts future viremia in persons with HIV (PWH) but there are few data from high-burden settings. We investigated whether TFV-DP in DBS predicts future viral breakthrough in South African PWH.